Two Sigma Advisers
CLDX icon

Two Sigma Advisers’s Celldex Therapeutics CLDX Stock Holding History

Two Sigma Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,600
Closed -$826K – 2394
2025
Q2 		$826K Buy
+40,600
New +$790K ﹤0.01% 1531
2024
Q2 		– Sell
-14,400
Closed -$604K – 2473
2024
Q1 		$604K Buy
+14,400
New +$591K ﹤0.01% 1796
2023
Q2 		– Sell
-36,200
Closed -$1.3M – 2416
2023
Q1 		$1.3M Sell
36,200
-30,400
-46% -$1.31M ﹤0.01% 1495
2022
Q4 		$2.97M Sell
66,600
-53,500
-45% -$1.91M 0.01% 1027
2022
Q3 		$3.38M Sell
120,100
-109,800
-48% -$3.37M 0.01% 922
2022
Q2 		$6.2M Buy
229,900
+75,900
+49% +$2.2M 0.02% 674
2022
Q1 		$5.25M Buy
154,000
+93,700
+155% +$3M 0.01% 781
2021
Q4 		$2.33M Buy
+60,300
New +$2.63M 0.01% 1117
2021
Q3 		– Sell
-87,736
Closed -$2.93M – 2471
2021
Q2 		$2.93M Sell
87,736
-122,520
-58% -$3.36M 0.01% 1113
2021
Q1 		$4.33M Sell
210,256
-191,300
-48% -$4.39M 0.01% 911
2020
Q4 		$7.04M Sell
401,556
-41,800
-9% -$752K 0.02% 699
2020
Q3 		$6.58M Buy
443,356
+387,300
+691% +$4.54M 0.02% 675
2020
Q2 		$729K Buy
+56,056
New +$248K ﹤0.01% 1725
2020
Q1 		– Sell
-16,497
Closed -$37K – 2470
2019
Q4 		$37K Sell
16,497
-3,900
-19% -$9.05K ﹤0.01% 2300
2019
Q3 		$43K Sell
20,397
-6,600
-24% -$15.3K ﹤0.01% 2159
2019
Q2 		$72K Sell
26,997
-2,900
-10% -$9.85K ﹤0.01% 2236
2019
Q1 		$147K Sell
29,897
-12,420
-29% -$65.3K ﹤0.01% 2158
2018
Q4 		$126K Sell
42,317
-306
-0.7% -$1.5K ﹤0.01% 2203
2018
Q3 		$288K Buy
42,623
+22,652
+113% +$159K ﹤0.01% 1968
2018
Q2 		$151K Buy
19,971
+17,908
+868% +$239K ﹤0.01% 2233
2018
Q1 		$72K Sell
2,063
-3,527
-63% -$137K ﹤0.01% 2239
2017
Q4 		$238K Buy
+5,590
New +$239K ﹤0.01% 2026
2015
Q1 		– Sell
-690
Closed -$189K – 1963
2014
Q4 		$189K Buy
+690
New +$172K ﹤0.01% 2228

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers's CLDX Position: Q3 2025 in Review

Two Sigma Advisers sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 40,600 shares — an estimated $826K sold.

Two Sigma Advisers first reported a position in CLDX in Q4 2014 and held it in 23 quarters. The position peaked at $7.04M in Q4 2020. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Two Sigma Advisers reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 40,600 Celldex Therapeutics shares in Q3 2025, an estimated $826K.
  • Two Sigma Advisers first reported a position in Celldex Therapeutics in Q4 2014 and held it in 23 quarters.
  • Two Sigma Advisers's Celldex Therapeutics position peaked at $7.04M in Q4 2020.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.